by David Brindley | Nov 13, 2014
. With contributions from James Smith, a recent Oxford University graduate and current CASMI Translational Stem Cell Consortium Research Associate In the early 1770s, Britain faced a significant financial dilemma. One of its most important commercial institutions,...
by Mark Curtis | Nov 10, 2014
. I had the pleasure of meeting Dr. Eytan Abraham over lunch on the first day of the Till & McCulloch Meetings, held last month in Ottawa (October 27-29). After some discussion about cell therapy manufacturing, I learned that he is the new Head of Research and...
by Mark Curtis | Nov 4, 2014
. Those following the regenerative medicine (RM) industry are likely in-tune with a rapidly evolving market, on the periphery, that is shaping up to provide a very attractive value proposition to patients, industry, and investors alike. The health care industry is...
by David Kent | Oct 28, 2014
> Last month, Signals re-posted a blog entry of mine from The Black Hole where I lamented the lack of teamwork in the life sciences. There are, however, always exceptions and I want to highlight one such exception that took the field of blood stem cell expansion by...
by Mark Curtis | Oct 14, 2014
. Welcome to your Update from the Clinic for the month of September. There’s a mixture of news from the cancer stem cell companies and immunotherapy companies this past month. Amongst other things, the FDA removed the previously imposed partial hold on one of...
by Mark Curtis | Oct 9, 2014
Welcome to your deal review for the month of September. There was some healthy news flow around cell-based immunotherapy companies this past month, heating up a space that is already ablaze with activity. Undoubtedly the company that took the spotlight was...
Comments